Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions

Myeloproliferative Diseases

Interventions

DRUG

ITF2357

50 mg b.i.d. PO every day. More precisely, ITF2357 was supplied as 50 mg hard gelatine capsules for oral administration.

Trial Locations (2)

Ospedali riuniti, Bergamo

IRCCS - Pol. San Matteo, Pavia